Konegra( sildenafil)

  • Jul 04, 2018
(Sildenafil)

Konegra( sildenafil) Instruction:

Manufacturer:

Active ingredients Conga:

Form of the Conga:

To whom is Konhera shown?

How to use Konigs? .

Take internally. Assign a dose of 50 mg for 1 hour before sexual intercourse. Taking into account the effectiveness and tolerability of the dose can be increased to 100 mg. The maximum recommended dose is 100 mg once a day.

In the elderly and patients with severe renal insufficiency( creatinine clearance less than 30 ml / min) or with a violation of liver function, the initial dose is 50 mg. Taking into account the effectiveness and tolerability of the dose can be increased to 100 mg.

To diagnose erectile dysfunction, determine their possible causes and choose an a

dequate treatment, you must collect a complete medical history and conduct a thorough physical examination of the patient. Sexual activity represents a certain risk in the presence of diseases of the cardiovascular system. Therefore, before starting treatment for erectile dysfunction, a cardiac examination of the patient is necessary. After widespread introduction of the drug, serious cardiovascular abnormalities were reported, including angina pectoris, myocardial infarction, sudden coronary death, ventricular arrhythmias, hemorrhagic stroke, ischemia, arterial hyper- or hypotension. These cases predominantly developed during or immediately after sexual activity. Most patients, but not all, had risk factors for developing cardiovascular diseases.

Drugs intended for the treatment of erectile dysfunction are cautiously prescribed to patients with anatomical deformation of the penis, for example, with angulation, cavernous fibrosis( Peyronie's disease) and persons with diseases promoting the development of priapism( sickle cell anemia, multiple myeloma or leukemia. There is no information on the safety of the use of the Koneg for peptic ulcers and hemorrhagic diathesis, which is why the drug is prescribed with caution for patients with this pathology.

For a small number of bhereditary retinitis pigmentary retinitis marked hereditary disorders of phosphodiesterase of the retina. No information about the safety of the use of Konegra patients with retinitis pigmentosa absent, so they should be prescribed with caution

Drugs intended for the treatment of erectile dysfunction should not be given to men for whom sexual activity is undesirable.

Because dizziness and visual impairment were observed during clinical trials of sildenafil, transport should not be administeredand work with potentially dangerous mechanisms until the individual reaction to the drug is elucidated.

Congestion Side Effects.

The drug is well tolerated. The most likely side effects are headache, blood rashes, dizziness, dyspeptic reactions, nasal congestion, transient visual impairment( mainly color changes in the perception of objects, as well as increased perception of light and blurring of vision), when the drug is administered at doses exceeding recommended, The undesirable phenomena were similar to those noted above, but were registered more often. Mialgia and cases of priapism were noted.

Who is contraindicated in Konegra?

Hypersensitivity to the drug;simultaneous use of donators NO or nitrates in any form;childhood.

The interaction of Konegra.

The safety and efficacy of the drug in combination with other agents intended for the treatment of erectile dysfunction have not been studied, therefore, such combinations should not be used.

Simultaneous administration of sildenafil and ritonavir, highly specific inhibitors of P-450 is not recommended. Simultaneous reception of HIV protease inhibitor ritonavir at the equilibrium concentration stage( 500 mg twice daily) with sildenafil( 100 ml once) leads to a 300% increase( 4-fold) of the maximum concentration of sildenafil in blood plasma and 1000%( 1 11 times) increaseAUC of sildenafil.

Cimetidine 800 mg, which is a nonspecific inhibitor of CYP3A4, with simultaneous administration with Camogra, caused an increase in the concentration of sildenafil in blood plasma by 56% in healthy volunteers. Population pharmacokinetic analysis of the results of a clinical trial demonstrated a decrease in the clearance of sildenafil with simultaneous use of CYP3A4 inhibitors( such as ketoconazole, erythromycin, cimetidine), but the incidence of side effects in these patients did not increase.

A one-time administration of an antacid( magnesium / aluminum hydroxide) did not affect the bioavailability of Konegra.

According to the population analysis, inhibitors of CYP2C9( tolbutimide, warfarin), CYP2D6( selective inhibitors of reverse neuronal uptake of serotonin, tricyclic antidepressants), thiazides and thiazide-like diuretics, loop and potassium-sparing diuretics, ACE inhibitors, calcium antagonists, β-adrenergic blockers and CYP450 metabolism inducers(rifampicin, barbiturates) had no effect on the pharmacokinetics of sildenafil. When using sildenafil in recommended doses, the maximum concentration in the blood plasma is about 1 μmol, therefore it is unlikely that Kongera is able to influence the clearance of the substrates of these isoenzymes.

Signs of significant interaction with tolbutamide at a dose of 250 mg or warfarin at a dose of 40 mg that metabolize CYP2C9 have not been identified.

Conger( 50 mg) did not increase the hypotensive effect of alcohol in healthy volunteers with a maximum alcohol level of 80 mg / dL on average. Patients with arterial hypertension had no signs of Konegra interaction( 100 mg) with amlodipine. The mean additional decrease in arterial pressure in the prone position( systolic - 8 mm Hg, diastolic - 7 mm Hg) was approaching this when taking a single Konegra in healthy volunteers. Data on safety of use indicate that there are no differences in the nature of side effects in patients who have received Konegra along with antihypertensive drugs and without them.

Overdose of Konegra.

In studies on healthy volunteers with a single dose of the drug at a dose of up to 800 mg, adverse events were similar to those seen with Conegra in lower doses, but were more common. In case of an overdose, a standard symptomatic treatment is performed. The use of dialysis probably does not increase the clearance of sildenafil, since the latter actively binds to plasma proteins and is not excreted in the urine.